Nolato has taken a significant step in its climate journey by setting ambitious science-based emissions targets, now validated by the Science Based Targets Initiative (SBTi), aligning the company’s efforts with the goals of the Paris Agreement to limit global warming.
Nolato provides the healthcare and pharmaceutical industries with end-to-end development and manufacturing solutions of advanced drug delivery systems such as pen-injectors, auto-injectors, wearable on-body injectors, inhalers, nebulizers and ophthalmic devices based on advanced injection molding and high-precision, high-speed automation.